Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®

• Main Authors: Ferdin, Roelfsema, Nienke R Biermasz, Alberto M Pereira, Johannes A Romijn
• Format: Article
• Language: English
• Published: Dove Medical Press 2008-09-01
• Series: Biologics : Targets & Therapy
• Online Access: http://www.dovepress.com/therapeutic-options-in-the-management-of-acromegaly-focus-on-lanreotid-a2296
• ISSN: 1177-5475; 1177-5491

Ferdinand Roelfsema, Nienke R Biermasz, Alberto M Pereira, Johannes A RomijnDepartment of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, The NetherlandsBackground: In acromegaly, expert surgery is curative in only about 60% of patients. Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its effect on growth hormone (GH) production is slow, so that adjuvant medical treatment becomes of importance in the management of many patients.Objective: To delineate the role of lanreotide in the treatment of acromegaly.Methods: Search of Medline, Embase, and Web of Science databases for clinical studies of lanreotide in acromegaly.Results: Treatment with lanreotide slow release and lanreotide Autogel® normalized GH and insulin-like growth factor-I (IGF-I) concentrations in about 50% of patients. The efficacy of 120 mg lanreotide Autogel® on GH and IGF-I levels was comparable with that of 20 mg octreotide LAR. There were no differences in improvement of cardiac function, decrease in pancreatic β-cell function, or occurrence of side effects, including cholelithiasis, between octreotide LAR and lanreotide Autogel®. When postoperative treatment with somatostatin analogs does not result in normalization of serum IGF-I and GH levels after noncurative surgery, pegvisomant alone or in combination with somatostatin analogs can control these levels in a substantial number of patients.Keywords: acromegaly, lanreotide, somatostatin analog, growth hormone, pegvisomant